New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
01:43 EDTVRX, GILD, ABTVertex Pharmaceuticals offers investors few catalysts, Barron's says
Vertex Pharmaceuticals (VRX) was once a Wall Street darling, but sales of its blockbuster hepatitis C drug, Incivek, are falling. And as Incivek sales keep falling, many worry that Vertex may start losing money next year. Q3 results disappointed investors. And shares sank Friday, as Goldman Sachs analyst Terence Flynn downgraded the stock to a Sell. The worry is that experimental cystic fibrosis drugs now in development may not prove to be potent enough to help patients. Also, Gilead Sciences (GILD) and Abbott Laboratories (ABT) have rival hepatitis C drugs in phase three trials, which Vertex won't start until 2014. Barron's contends that Vertex faces challenges that make the stock unattractive even at a marked-down price. Reference Link
News For VRX;ABT;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
09:33 EDTVRXZoetis could get bought by Bayer for $53/share, says Jefferies
Subscribe for More Information
07:23 EDTVRXValeant wooing doctors ahead of hoped for Allergan acquisition, WSJ says
Subscribe for More Information
November 12, 2014
10:09 EDTVRXActavis in talks to buy Allergan for over $200 per share, Bloomberg says
Subscribe for More Information
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
06:22 EDTVRXZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
November 11, 2014
16:24 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
16:14 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
15:46 EDTVRXPershing Square, Sachem Head build 10% stake in Zoetis, WSJ reports
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
08:32 EDTVRXValeant likely to raise offer for Allergan again, says Bernstein
Subscribe for More Information
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
November 10, 2014
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:20 EDTGILDOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTGILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTGILDGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
13:26 EDTVRXAckman's Allergan court win may prove costly down the road, Bloomberg says
When U.S. District Court Judge David Carter ruled on November 4 that Pershing Square can vote its 9.7% stake in Allergan (AGN) in a shareholder ballot aiming to remove Allergan directors, he also noted that there were “serious questions” regarding insider trading rules in the way Pershing Square acquired Allergan stock while preparing a bid with Valeant (VRX), says Bloomberg. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use